BIOEMISSION TECHNOLOGY SOLUTIONS SA

Their core work

BIOEMTECH is a Greek SME specializing in preclinical and medical imaging technologies, with deep expertise in multimodal bio-imaging and nanoparticle-based theranostics. They develop and apply imaging solutions for tracking biological processes — from stem cell therapies and bone transplants to cancer diagnostics and drug delivery monitoring. Their work bridges imaging hardware/software with nanomedicine, making them a technical partner for projects that need to visualize what happens inside the body at high resolution. They also contribute to physical phantom development for medical imaging calibration and quality assurance.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2019), BIOEMTECH focused on multimodal imaging for regenerative medicine — tracking bone transplants, monitoring nanoparticle-based drug delivery for cardiovascular disease, and developing pediatric dosimetry tools. From 2018 onward, their work shifted decisively toward cancer applications: breast cancer modeling, cancer theranostics with nanohybrids, and physical breast phantoms for imaging calibration. There is also a growing thread of biofabrication and advanced materials (bioprinting, microfluidics, green sonochemistry), suggesting they are expanding beyond pure imaging into the tissue engineering space.

BIOEMTECH is converging on cancer-focused imaging and diagnostics, combining their imaging roots with biofabricated tissue models and nanomedicine — expect them to pursue precision oncology imaging projects next.

How they like to work

BIOEMTECH operates exclusively as a participant, never as coordinator, across all 9 projects — a clear specialist contributor profile. With 63 unique consortium partners across 21 countries, they join large, international research consortia (typical of MSCA-RISE networks) rather than leading small teams. This pattern suggests they bring a specific technical capability (imaging, phantom development) that many different research groups need, making them easy to integrate into diverse consortia without taking on project management overhead.

Extensive European network spanning 63 partners across 21 countries, built primarily through MSCA-RISE mobility networks. This broad reach across most of the EU research landscape makes them well-connected despite being a small SME.

What sets them apart

BIOEMTECH occupies a rare niche as a private SME with deep preclinical imaging expertise — most companies in this space are either large medical device firms or university labs. Their ability to contribute imaging technology across very different biomedical applications (cardiovascular, musculoskeletal, oncology, pediatric) makes them unusually versatile. For consortium builders, they offer a reliable imaging and phantom development partner with proven experience in 9 EU projects and no coordination overhead.

Highlights from their portfolio

• nTRACK
  Largest single project by funding (EUR 832,762) — multimodal nanoparticle tracking for stem cell therapy in muscle regeneration, representing their core imaging-meets-nanomedicine expertise.
• PHENOMENO
  Demonstrates their 3D printing and phantom fabrication capability for breast imaging across MRI, CT, and mammography — a growing market need for imaging standardization.
• B2B
  Unusual combination of bioprinting, microfluidics, and cancer tissue engineering — signals their expansion from imaging into biofabrication and personalized medicine platforms.